1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy
Key Takeaways
- HELLP syndrome is defined by the laboratory triad of microangiopathic Hemolysis (schistocytes on blood smear, total bilirubin ≥1.2 mg/dL, LDH >600 U/L), Elevated Liver enzymes (AST and ALT ≥2 times upper limit of normal), and Low Platelets (<100,000/μL).
- The Mississippi Triple-Class System classifies HELLP based on the nadir platelet count: Class 1 (platelets ≤50,000/μL, AST/ALT ≥70 U/L, LDH >600 U/L), Class 2 (platelets 50,001-100,000/μL), and Class 3 (platelets 100,001-150,000/μL, AST/ALT ≥40 U/L, LDH >600 U/L).
- Acute Fatty Liver of Pregnancy (AFLP) is a life-threatening obstetric emergency linked to fetal long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, diagnosed by the Swansea criteria (≥6 required) and characterized by profound refractory hypoglycemia, hyperammonemia, elevated uric acid, and coagulopathy/DIC.
- Intrahepatic Cholestasis of Pregnancy (ICP) presents with intense pruritus without primary rash, primarily on palms and soles with nocturnal exacerbation; diagnosis is confirmed by elevated total serum bile acids (TBA ≥10 μmol/L), treated with first-line ursodeoxycholic acid (UDCA), and delivered at 36 0/7 to 39 0/7 weeks (or at 36 0/7 weeks if TBA ≥100 μmol/L).
- Platelet transfusion is indicated in HELLP syndrome prior to delivery if platelet count is <20,000/μL for vaginal delivery or <50,000/μL for cesarean delivery; neuraxial anesthesia is generally avoided when platelets are <70,000-80,000/μL or rapidly falling.
Pathophysiology and Clinical Manifestation of HELLP Syndrome
HELLP syndrome is a severe, life-threatening manifestation of systemic endothelial injury that occurs in approximately 0.5% to 0.9% of all pregnancies and in 10% to 20% of women with severe preeclampsia. Crucially, up to 15% to 20% of patients with HELLP syndrome do not exhibit antecedent hypertension or proteinuria, frequently leading to delayed diagnosis or misdiagnosis as acute cholecystitis, gastroenteritis, or viral hepatitis.
The syndrome represents an acronym defining its core laboratory triad:
- H (Hemolysis): Microangiopathic hemolytic anemia resulting from the mechanical fragmentation of erythrocytes as they are forced at high pressure through constricted, damaged vascular beds lined with meshworks of fibrin strands.
- EL (Elevated Liver Enzymes): Obstruction of hepatic sinusoidal blood flow by microvascular fibrin deposits, leading to localized hepatocyte ischemia, cellular swelling, periportal necrosis, and capsular distension.
- LP (Low Platelets): Accelerated consumption and destruction of platelets at widespread sites of endothelial damage, far exceeding the bone marrow's megakaryocyte compensatory capacity.
Clinical Presentation and Warning Signs
The onset of HELLP syndrome is typically insidious, with rapid escalation over 24 to 48 hours. Patients characteristically present with:
- Right Upper Quadrant (RUQ) or Epigastric Pain (85–90%): Caused by microvascular congestion and stretching of the hepatic Glisson's capsule. Pain is frequently described as constant, aching, or throbbing, and may radiate to the right flank, back, or right shoulder.
- Malaise, Nausea, and Vomiting (50–60%): Often mistaken for viral gastroenteritis or reflux.
- Edema and Sudden Weight Gain (60%): Resulting from generalized capillary leakage.
- Visual Symptoms and Headache (30–60%): Reflecting cerebral endothelial involvement.
+-------------------------------------------------------------------------------------------------------------------+
| HELLP SYNDROME DIAGNOSTIC CRITERIA |
+-------------------------------------------------------------------------------------------------------------------+
Diagnostic Component Laboratory Parameter / Diagnostic Threshold
-------------------- -------------------------------------------------------------------------------------
1. HEMOLYSIS (H) - Abnormal peripheral blood smear demonstrating Schistocytes, Burr cells, or Helmet cells
- Serum Lactate Dehydrogenase (LDH) >600 U/L
- Total Serum Bilirubin ≥1.2 mg/dL (predominantly indirect/unconjugated)
- Low or undetectable serum Haptoglobin (<25 mg/dL)
-------------------------------------------------------------------------------------------------------------------
2. ELEVATED LIVER - Serum Aspartate Aminotransferase (AST) ≥70 U/L (or ≥2 times upper limit of normal)
ENZYMES (EL) - Serum Alanine Aminotransferase (ALT) ≥2 times upper limit of normal
-------------------------------------------------------------------------------------------------------------------
3. LOW PLATELETS (LP) - Platelet count <100,000/μL (severe thrombocytopenia)
+-------------------------------------------------------------------------------------------------------------------+
Classification Systems
Two validated systems are utilized in clinical practice:
- Tennessee Classification (Strict Criteria): Complete HELLP requires all three components: microangiopathic hemolysis (LDH >600 U/L, abnormal smear), AST ≥70 U/L, and platelets <100,000/μL. Partial or incomplete HELLP (ELLP or HEL) carries similar maternal risk and mandates identical aggressive management.
- Mississippi Triple-Class System (Prognostic Stratification):
- Class 1 (Severe): Platelets ≤50,000/μL; LDH >600 U/L; AST/ALT ≥70 U/L. Highest risk of maternal mortality, DIC, renal failure, and hepatic hematoma.
- Class 2 (Moderate): Platelets >50,000 to ≤100,000/μL; LDH >600 U/L; AST/ALT ≥70 U/L.
- Class 3 (Mild / Resolving): Platelets >100,000 to ≤150,000/μL; LDH >600 U/L; AST/ALT ≥40 U/L.
Hepatic Catastrophes: Subcapsular Hematoma and Rupture
A catastrophic complication of HELLP syndrome is the development of a hepatic subcapsular hematoma and subsequent hepatic parenchymal rupture, occurring in 1% to 2% of HELLP cases. Extensive sinusoidal thrombosis leads to localized parenchymal infarction, intrahepatic hemorrhage, and progressive dissection of blood beneath Glisson's capsule. Rupture occurs when intra-capsular pressure exceeds the structural integrity of the capsule.
Clinical Presentation of Hepatic Rupture
- Sudden, tearing, excruciating RUQ pain radiating into the right shoulder (phrenic nerve irritation / Kehr's sign).
- Sudden profound maternal hypotension, hypovolemic shock, pallor, diaphoresis, and cardiovascular collapse.
- Acute abdominal distension and peritoneal signs (rebound tenderness, rigidity).
Urgent Nursing and Surgical Interventions
- Immediate Hemodynamic Resuscitation: Place two large-bore IV lines (14- or 16-gauge) or central venous access; activate the hospital Massive Transfusion Protocol (MTP) immediately.
- Urgent Diagnostic Imaging: Bedside Focused Assessment with Sonography for Trauma (FAST) or emergency abdominal CT scan (if hemodynamically stable enough) to visualize free intra-abdominal fluid and hepatic parenchymal disruption.
- Emergent Surgical Intervention: Immediate exploratory laparotomy with an interdisciplinary surgical team (maternal-fetal medicine, trauma/transplant surgery). Surgical management includes hepatic packing, primary surgical ligation, application of topical hemostatic agents, or transcatheter hepatic arterial embolization (TAE).
- Correction of Coagulopathy: Rapid transfusion of packed red blood cells, fresh frozen plasma (FFP), cryoprecipitate (to maintain fibrinogen >200 mg/dL), and platelets.
Acute Fatty Liver of Pregnancy (AFLP)
Acute Fatty Liver of Pregnancy (AFLP) is an uncommon (1 in 10,000 to 1 in 20,000 pregnancies) but catastrophic obstetric emergency characterized by microvesicular fatty infiltration of hepatocytes, culminating in acute maternal liver failure, encephalopathy, and disseminated intravascular coagulation. It typically presents in the late third trimester (30–38 weeks) or early postpartum period.
Pathophysiology and Genetics
AFLP is strongly associated with an inherited fetal defect in mitochondrial fatty acid beta-oxidation, specifically a deficiency in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) (most commonly the G1528C mutation). The heterozygous mother cannot adequately metabolize the excessive load of intermediate long-chain fatty acids produced by the homozygous LCHAD-deficient fetus and placenta, causing toxic accumulation of free fatty acids in maternal hepatocytes, which disrupts mitochondrial energy production.
Diagnostic Criteria: The Swansea Diagnostic Criteria
The diagnosis of AFLP is established clinically using the Swansea Criteria; the presence of 6 or more criteria in the absence of an alternative explanation confirms AFLP:
+-------------------------------------------------------------------------------------------------------------------+
| SWANSEA CRITERIA FOR AFLP (≥6 REQUIRED) |
+-------------------------------------------------------------------------------------------------------------------+
Clinical Findings Laboratory & Imaging Findings
----------------- -----------------------------
1. Vomiting 6. Total Bilirubin >14 μmol/L (>0.8 mg/dL)
2. Abdominal pain (Epigastric/RUQ) 7. Hypoglycemia <4.0 mmol/L (<72 mg/dL) [PROFOUND / REFRACTORY]
3. Polydipsia / Polyuria (DI) 8. Elevated Serum Uric Acid >340 μmol/L (>5.7 mg/dL)
4. Hepatic Encephalopathy (Asterixis) 9. Leukocytosis (WBC >11.0 x 10^9/L)
5. Microvesicular steatosis on biopsy 10. Elevated Transaminases (AST or ALT >42 U/L)
11. Hyperammonemia (>47 μmol/L) [Causes Encephalopathy]
12. Renal Impairment (Creatinine >150 μmol/L or >1.7 mg/dL)
13. Coagulopathy (PT >14 seconds or aPTT >34 seconds, low Fibrinogen)
14. Bright liver or ascites on ultrasound / CT
+-------------------------------------------------------------------------------------------------------------------+
Critical Clinical Distinctions: AFLP vs. HELLP
While both disorders present with RUQ pain and elevated transaminases, AFLP is uniquely distinguished by:
- Profound, refractory hypoglycemia (blood glucose often <50 mg/dL) due to impaired hepatic gluconeogenesis and glycogenolysis; requires continuous IV 10% or 20% dextrose infusions.
- Marked Coagulopathy / Prolonged PT/INR and aPTT occurring early in the disease process prior to delivery, whereas HELLP primarily features thrombocytopenia with preserved coagulation times until advanced DIC develops.
- Hyperammonemia and Encephalopathy with asterixis, confusion, and lethargy.
- Diabetes Insipidus (polydipsia, polyuria) secondary to decreased hepatic clearance of placental vasopressinase.
Intrahepatic Cholestasis of Pregnancy (ICP)
Intrahepatic Cholestasis of Pregnancy (ICP) is the most common gestational liver disorder, affecting 0.5% to 2% of pregnancies. It is caused by genetic susceptibility in hepatocellular bile acid transport proteins (e.g., ABCB4/MDR3 mutations) coupled with elevated circulating levels of estrogen and progesterone metabolites, which inhibit bile acid export from hepatocytes into the biliary canaliculus.
Clinical Presentation and Laboratory Diagnosis
- Pruritus (Hallmark): Intense, relentless itching characteristically localized to the palms of the hands and soles of the feet, with pronounced nocturnal worsening leading to severe sleep deprivation. Importantly, there is NO primary dermatologic rash (excoriations and scratch marks are secondary to intense itching).
- Jaundice (10–15%): Typically develops 1 to 4 weeks after the onset of pruritus.
- Total Serum Bile Acids (TBA): The definitive diagnostic test. A fasting or postprandial TBA ≥10 μmol/L confirms the diagnosis.
Risk Stratification and Fetal Risks
Elevated maternal bile acids cross the placenta and accumulate in the fetal compartment, causing direct fetal toxicity:
- Mild Cholestasis: TBA 10 to 39 μmol/L (low risk of fetal mortality).
- Moderate Cholestasis: TBA 40 to 99 μmol/L.
- Severe Cholestasis: TBA ≥100 μmol/L (highest risk; associated with a dramatic surge in sudden intrauterine fetal demise, spontaneous preterm birth, and meconium aspiration).
Fetal demise in ICP is sudden and unpredictable, resulting from acute bile acid-induced fetal cardiac dysrhythmias (conduction block) or sudden acute vasospasm of placental chorionic surface vessels. Standard antepartum testing (non-stress tests, biophysical profiles) does NOT reliably predict or prevent sudden stillbirth in severe ICP.
Pharmacologic Management and Delivery Timing
- First-Line Pharmacotherapy: Ursodeoxycholic Acid (UDCA / Actigall): 10 to 15 mg/kg/day orally (typically 300 mg BID or TID, up to 600–900 mg TID). UDCA is a hydrophilic bile acid that displaces cytotoxic hydrophobic bile acids, enhances biliary export, relieves maternal pruritus within 1–2 weeks, and normalizes serum transaminases and bile acid levels.
- Delivery Timing Protocol (ACOG / SMFM Guidelines):
- TBA 10 to 39 μmol/L (Mild): Delivery at 36 0/7 to 39 0/7 weeks of gestation.
- TBA 40 to 99 μmol/L (Moderate): Delivery at 36 0/7 to 39 0/7 weeks of gestation (often individualized around 36–37 weeks).
- TBA ≥100 μmol/L (Severe): Planned delivery at 36 0/7 weeks of gestation (or upon diagnosis if diagnosed later) due to the steep increase in stillbirth risk beyond 36 weeks.
Differential Diagnosis of Hepatic Disorders in Pregnancy
| Feature | HELLP Syndrome | Acute Fatty Liver (AFLP) | Intrahepatic Cholestasis (ICP) | Acute Cholecystitis |
|---|---|---|---|---|
| Gestational Age | 27 weeks to 48h postpartum | Late 3rd trimester to postpartum | Late 2nd to 3rd trimester | Any trimester |
| Primary Symptoms | RUQ pain, nausea, malaise, edema | Vomiting, abdominal pain, polydipsia, confusion | Intense palmar/plantar pruritus without rash | Colicky RUQ pain after fatty meals, Murphy's sign |
| Blood Pressure | Usually elevated (80-85%) | Variable / Normal | Normal | Normal |
| Transaminases (AST/ALT) | Elevated (≥70 to >1000 U/L) | Elevated (100–1000 U/L) | Mildly elevated (2–5x ULN) | Mildly elevated or normal |
| Platelet Count | Severely Low (<100,000/μL) | Low to Normal (consumptive) | Normal | Normal |
| Coagulation (PT/aPTT) | Normal until advanced DIC | Markedly Prolonged early | Normal | Normal |
| Serum Glucose | Normal | Profound Hypoglycemia (<50) | Normal | Normal |
| Serum Bile Acids | Normal or mildly elevated | Moderately elevated | Elevated (≥10 to >100 μmol/L) | Normal |
| Primary Treatment | Immediate delivery, $MgSO_4$, antihypertensives | Immediate delivery, IV glucose, ICU supportive care | Ursodeoxycholic acid, planned delivery 36–39 wk | Bowel rest, IV fluids, IV antibiotics, cholecystectomy |
Inpatient Nursing Priorities for HELLP and Acute Hepatic Disease
- Hemodynamic and Neurologic Surveillance: Continuous blood pressure monitoring, seizure prophylaxis with IV magnesium sulfate (4-6 g load, 1-2 g/hr maintenance), hourly assessment of DTRs, clonus, and mental status.
- Serial Laboratory Monitoring: Stat CBC with platelet count, comprehensive metabolic panel (AST, ALT, creatinine, bilirubin), LDH, fibrinogen, PT/INR, and aPTT drawn every 6 to 12 hours until clear improvement is demonstrated postpartum.
- Platelet Transfusion Protocols:
- Platelet count <20,000/μL: Transfuse 1 apheresis unit of platelets immediately, regardless of delivery mode.
- Platelet count <50,000/μL: Transfuse platelets prior to planned cesarean delivery.
- Platelets <70,000–80,000/μL: Neuraxial anesthesia (spinal/epidural) is contraindicated due to the risk of epidural hematoma and spinal cord compression. General anesthesia is typically required for cesarean birth.
- Postpartum Course Anticipation: Maternal laboratory parameters characteristically worsen during the first 24 to 48 hours postpartum, with the nadir of thrombocytopenia and peak of LDH occurring at 24 to 48 hours post-delivery. Clinical recovery, signaled by an upward trend in platelet count (>100,000/μL) and downward trend in transaminases, typically begins by postpartum day 3 to 4.
A 28-year-old multigravida at 34 weeks of gestation presents to triage complaining of severe, unremitting right upper quadrant pain and nausea for the past 24 hours. Vital signs: BP 138/88 mmHg, HR 82 bpm, RR 18 breaths/min. Laboratory analysis reveals: Platelets 64,000/μL, AST 184 U/L, ALT 162 U/L, total bilirubin 1.8 mg/dL, LDH 720 U/L, and blood glucose 94 mg/dL. Coagulation profile (PT/INR and aPTT) is normal. Which clinical condition and classification best describe these findings?
A patient at 36 weeks of gestation with severe HELLP syndrome is being prepared for an urgent cesarean delivery due to a Category III fetal heart rate tracing. The patient's platelet count is 32,000/μL. What is the priority nursing intervention regarding blood product preparation and anesthesia planning?
A 34-week primigravida presents with intractable palmar and plantar itching that worsens significantly at night. She has no skin rash. Laboratory workup reveals serum AST 56 U/L, ALT 62 U/L, total bilirubin 1.0 mg/dL, platelet count 210,000/μL, and total serum bile acids (TBA) of 115 μmol/L. What is the most appropriate medical management and planned delivery timing for this patient?
A patient at 35 weeks of gestation is admitted with persistent vomiting, severe epigastric pain, confusion, and extreme thirst (polydipsia). Laboratory evaluation reveals: AST 320 U/L, ALT 290 U/L, Total Bilirubin 4.2 mg/dL, Serum Ammonia 85 μmol/L, Serum Creatinine 2.1 mg/dL, PT 22 seconds, Fibrinogen 110 mg/dL, and Blood Glucose 38 mg/dL. What is the primary diagnosis and immediate medical management?